SPRY
ARS Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +25.0% ·
share flow +30.0% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 74 | +1 | 32.54M | $260.86M | +8 | −7 |
| Q1 2026 | 76 | +2 | 39.92M | $320.66M | +9 | −7 |
| Q4 2025 | 74 | +1 | 37.60M | $438.08M | +2 | −1 |
| Q3 2025 | 13 | -4 | 17.49M | $175.83M | +1 | −5 |
| Q2 2025 | 14 | 0 | 19.24M | $335.74M | +1 | −1 |
| Q1 2025 | 11 | +2 | 5.28M | $66.41M | +2 | — |
| Q4 2024 | 9 | -2 | 6.14M | $64.82M | — | −2 |
| Q3 2024 | 10 | +2 | 3.52M | $51.10M | +3 | −1 |
| Q2 2024 | 8 | — | 1.67M | $14.24M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.23M | +3.3% | $17.91M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.23M | +3.3% | $17.91M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Duquesne Family Office ✦ | 536.90K | New | $7.79M | 0.3% | New | 1 | SEC ↗ |
| 4 | Millennium Management ✦ | 486.75K | New | $7.06M | 0.0% | New | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 462.52K | +2842.2% | $6.71M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 462.52K | +2842.2% | $6.71M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 252.50K | +178.2% | $3.66M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 252.50K | +178.2% | $3.66M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 214.06K | +356.2% | $3.10M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 162.34K | +38.9% | $2.35M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 162.34K | +38.9% | $2.35M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 80.55K | +18.1% | $1.17M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 80.55K | +18.1% | $1.17M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Marshall Wace ✦ | 77.88K | New | $1.13M | 0.0% | New | 1 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 15.80K | -87.3% | $229,100 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Duquesne Family Office | $7.79M | 0.3% |
| Millennium Management | $7.06M | 0.0% |
| Marshall Wace | $1.13M | 0.0% |
Exited
| Arrowstreet Capital | $127,000 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 201 holders, 92.94M shares, $730.00M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.